Amgen (AMGN), in its earnings report last night, said its Phase 2 study investigating MariTide for the treatment of Type 2 diabetes diabetes is ongoing in adults living with and without obesity is expected to readout in Q4 of 2025. The company previously guided the readout for the second half of 2025. Shares of Amgen are down 5% to $285.70 in morning trading following the Q2 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- Amgen’s Strong Performance and Promising Pipeline Drive Buy Rating
- Amgen price target lowered to $317 from $326 at UBS
- Amgen price target raised to $310 from $305 at Citi
- Amgen Inc. Reports Strong Q2 2025 Financial Results